Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Another Day, Another Opioid Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

As opioid plan shifts into high gear, FDA sets June dates for proposed abuse-deterrent opioids from Teva and Pfizer that already have missed user fee goals.



Related Companies